Patents by Inventor Hangjun Zhan
Hangjun Zhan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970526Abstract: Provided are various embodiments relating to interleukin 13 receptor subunit alpha-1/interleukin 4 receptor subunit alpha (IL13R/IL4R) contiguous polypeptides derived from companion animal species and that bind to IL13 and/or IL4. Such contiguous polypeptides can be used in methods to treat IL13 and/or IL4-induced conditions in companion animals, such as canines, felines, and equines.Type: GrantFiled: April 20, 2018Date of Patent: April 30, 2024Assignee: Elanco US Inc.Inventors: Hangjun Zhan, Lam Nguyen, Fawn Qian, Shyr Jiann Li
-
Publication number: 20240101660Abstract: Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.Type: ApplicationFiled: May 3, 2023Publication date: March 28, 2024Inventors: Shyr Jiann Li, Lam Nguyen, Hangjun Zhan
-
Publication number: 20240101715Abstract: Provided are various embodiments relating to caninized TNF? antibodies and caninized NGF antibodies. Such antibodies can be used in methods to treat canines with inflammatory conditions, such as inflammatory bowel disease and/or in methods to treat canines with pain, such as osteoarthrititic pain, back pain, cancer pain, and/or a neuropathic pain.Type: ApplicationFiled: December 17, 2021Publication date: March 28, 2024Inventors: Stephanie A. PIERCE, Leonard PRESTA, Shyr Jiann LI, Lam NGUYEN, Richard CHIN, Hangjun ZHAN
-
Publication number: 20240067738Abstract: Provided are various embodiments relating to anti-IL4R antibodies that bind to canine IL4R. In various embodiments, such anti-IL4R antibodies can be used in methods to treat IL4/IL13-induced conditions, such as atopic dermatitis, allergic dermatitis, pruritus, asthma, psoriasis, scleroderma and eczema, in companion animals, such as canines and felines. Also provided are various embodiments relating to variant IgG Fc polypeptides and variant light chain constant regions of companion animal species for the preparation of antibodies or bispecific antibodies.Type: ApplicationFiled: March 17, 2021Publication date: February 29, 2024Inventors: Shyr Jiann LI, Lam NGUYEN, Richard CHIN, Hangjun ZHAN, Qingyi CHU
-
Publication number: 20230416323Abstract: Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals. Also provided are various embodiments relating to EPO polypeptides having a mutation in the second binding site, polypeptides comprising an extracellular domain of EPO receptor, and methods of using the same for treating polycythemia in mammals.Type: ApplicationFiled: May 30, 2023Publication date: December 28, 2023Inventors: Hangjun Zhan, Lam Nguyen, Yongzhong Li, Qingyi Chu, Estela Garcia-Murillo, Victoria Leitman, Stephen Sundlof, Richard Chin, Shyr Jiann Li
-
Publication number: 20230365672Abstract: Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.Type: ApplicationFiled: May 24, 2023Publication date: November 16, 2023Inventors: Shyr Jiann LI, Lam NGUYEN, Hangjun ZHAN
-
Publication number: 20230312702Abstract: Provided are various embodiments relating to long-acting anti-IL31 antibodies binding to canine IL31 and/or feline IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.Type: ApplicationFiled: April 22, 2021Publication date: October 5, 2023Inventors: Shyr Jiann LI, Lam NGUYEN, Qingyi CHU, Richard CHIN, Hangjun ZHAN
-
Patent number: 11697683Abstract: Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.Type: GrantFiled: September 30, 2020Date of Patent: July 11, 2023Assignee: Kindred Biosciences, Inc.Inventors: Shyr Jiann Li, Lam Nguyen, Hangjun Zhan
-
Patent number: 11673946Abstract: Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.Type: GrantFiled: February 9, 2018Date of Patent: June 13, 2023Assignee: Kindred Biosciences, Inc.Inventors: Shyr Jiann Li, Lam Nguyen, Hangjun Zhan
-
Patent number: 11667686Abstract: Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals. Also provided are various embodiments relating to EPO polypeptides having a mutation in the second binding site, polypeptides comprising an extracellular domain of EPO receptor, and methods of using the same for treating polycythemia in mammals.Type: GrantFiled: June 5, 2018Date of Patent: June 6, 2023Assignee: Kindred Biosciences, Inc.Inventors: Hangjun Zhan, Lam Nguyen, Yongzhong Li, Qingyi Chu, Estela Garcia-Murillo, Victoria Leitman, Stephen Sundlof, Richard Chin, Shyr Jiann Li
-
Publication number: 20220324960Abstract: Provided are various embodiments relating to anti-IL31 antibodies having enhanced binding to canine IL31 and feline IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines and felines. Antibodies with enhanced binding to canine IL31 and feline IL31 are provided Antibody heavy chains and light chains that are capable of forming antibodies that bind canine and feline IL31 are also provided.Type: ApplicationFiled: August 28, 2020Publication date: October 13, 2022Applicant: Kindred Biosciences, Inc.Inventors: Shyr Jiann Li, Lam Nguyen, Hangjun Zhan
-
Publication number: 20220267414Abstract: Provided are various embodiments relating to parvovirus antibodies, including caninized, felinized, and chimeric antibodies, that bind to canine and/or feline parvovirus, for example, having improved expression characteristics. In various embodiments, the parvovirus antibodies have ADCC, ADCP, and/or CDC effector functions. In various embodiments, such monoclonal parvovirus antibodies can be used in methods to prevent and/or treat parvoviral infection in subjects, such as dogs and cats. For example, the parvovirus antibodies provided may be used to provide passive immunity against infection with a canine or feline parvovirus.Type: ApplicationFiled: July 30, 2020Publication date: August 25, 2022Applicant: Kindred Biosciences, Inc.Inventors: Hangjun Zhan, Lam Nguyen, Ellen Ratcliff, Richard Chin, Shyr Jiann Li
-
Publication number: 20220185879Abstract: Provided are various embodiments relating to anti-IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A. In various embodiments, such anti-IL17A antibodies or IL17Ra ECD polypeptides can be used in methods to treat IL17-induced conditions in subjects, such as humans or companion animals, such as canines, felines, and equines. Also provided are various embodiments relating to IgG Fc variant polypeptides having one or more amino acid substitutions for reducing binding to C1q and/or CD16. In some embodiments, the IgG Fc variants and/or polypeptides comprising the IgG Fc variants (e.g., fusion polypeptides comprising the IgG Fc variants and the anti-IL17A antibodies and/or IL17Ra ECD polypeptides described herein) may have reduced complement-mediated immune responses and/or antibody-dependent cell-mediated cytotoxicity.Type: ApplicationFiled: March 4, 2022Publication date: June 16, 2022Applicant: Kindred Biosciences, Inc.Inventors: Shyr Jiann Li, Lam Nguyen, Lan Yang, Hangjun Zhan
-
Publication number: 20220169740Abstract: Provided are various embodiments relating to TrkA ECD polypeptides from companion animal species that bind to NGF. Such polypeptides can be used in methods to treat NGF-induced condition related to chronic pain and/or inflammatory pain in companion animals, such as canines, felines, and equines.Type: ApplicationFiled: March 20, 2020Publication date: June 2, 2022Applicant: Kindred Biosciences, Inc.Inventors: Hangjun Zhan, Lam Nguyen, Richard Chin, Fawn Qian, Shyr Jiann Li, Qingyi Chu
-
Patent number: 11299540Abstract: Provided are various embodiments relating to anti-IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A. In various embodiments, such anti-IL17A antibodies or IL17Ra ECD polypeptides can be used in methods to treat IL17-induced conditions in subjects, such as humans or companion animals, such as canines, felines, and equines. Also provided are various embodiments relating to IgG Fc variant polypeptides having one or more amino acid substitutions for reducing binding to C1q and/or CD16. In some embodiments, the IgG Fc variants and/or polypeptides comprising the IgG Fc variants (e.g., fusion polypeptides comprising the IgG Fc variants and the anti-IL17A antibodies and/or IL17Ra ECD polypeptides described herein) may have reduced complement-mediated immune responses and/or antibody-dependent cell-mediated cytotoxicity.Type: GrantFiled: June 18, 2018Date of Patent: April 12, 2022Assignee: Kindred Biosciences, Inc.Inventors: Shyr Jiann Li, Lam Nguyen, Lan Yang, Hangjun Zhan
-
Publication number: 20220064263Abstract: Provided are various embodiments relating to variant IgG Fc polypeptides of companion animals having increased Protein A binding for ease of purification, decreased C1q binding for reduced complement-mediated immune responses, decreased CD 16 binding (e.g., for reduced antibody-dependent cellular cytotoxicity (ADCC) induction), increased stability, and/or the ability to form multimeric proteins. In addition, various embodiments relating to antibodies and fusion proteins comprising such variant IgG Fc polypeptides are provided. In various embodiments, such polypeptides may be used to treat companion animals, such as canines, felines, and equines.Type: ApplicationFiled: December 26, 2019Publication date: March 3, 2022Applicant: Kindred Biosciences, Inc.Inventors: Hangjun Zhan, Lam Nguyen, Yongzhong Li, Fawn Qian, Shyr Jiann Li, Richard Chin
-
Publication number: 20220049002Abstract: Provided are various embodiments relating to anti-IL4R antibodies that bind to canine IL4R. In various embodiments, such anti-IL4R antibodies can be used in methods to treat IL4/IL13-induced conditions, such as atopic dermatitis, allergic dermatitis, pruritus, asthma, psoriasis, scleroderma and eczema, in companion animals, such as canines and felines. Also provided are various embodiments relating to variant IgG Fc polypeptides and variant light chain constant regions of companion animal species for the preparation of antibodies or bispecific antibodies.Type: ApplicationFiled: September 14, 2019Publication date: February 17, 2022Applicant: Kindred Biosciences, Inc.Inventors: Shyr Jiann Li, Lam Nguyen, Richard Chin, Hangjun Zhan
-
Publication number: 20220025005Abstract: Provided are various embodiments relating to erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and/or additional cysteine residues and methods of producing and using the same to treat anemia in companion animals. Also provided are various embodiments relating to polypeptides comprising an extracellular domain of EPO receptor and methods of using the same for treating polycythemia in mammals.Type: ApplicationFiled: December 12, 2019Publication date: January 27, 2022Applicant: Kindred Biosciences, Inc.Inventors: Hangjun Zhan, Lam Nguyen, Qingyi Chu, Shyr Jiann Li
-
Publication number: 20210395340Abstract: Provided are various embodiments relating to IL13R/IL4R heterodimeric proteins derived from companion animal species and that bind to IL13 and/or IL4. Such heterodimeric proteins can be used in methods to treat IL13 and/or IL4-induced conditions in companion animals, such as canines, felines, and equines.Type: ApplicationFiled: October 24, 2019Publication date: December 23, 2021Applicant: Kindred Biosciences, Inc.Inventors: Hangjun Zhan, Lam Nguyen, Fawn Qian, Shyr Jiann Li
-
Publication number: 20210388053Abstract: Provided are various embodiments relating to variant IgG Fc polypeptides with altered FcRn binding activity. Also provided are polypeptides and pharmaceutical compositions comprising the variant IgG Fc polypeptides described herein. Polypeptides comprising variant IgG Fc polypeptides of the present invention may have extended half-life in vivo. Such products may be used in methods to treat disease in companion animals, such as canines, felines, and equines.Type: ApplicationFiled: October 18, 2019Publication date: December 16, 2021Applicant: Kindred Biosciences, Inc.Inventors: Hangjun Zhan, Lam Nguyen, Qingyi Chu, Richard Chin, Shyr Jiann Li